283 related articles for article (PubMed ID: 29720397)
21. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
22. Arrhythmia associated with buprenorphine and methadone reported to the Food and Drug Administration.
Kao DP; Haigney MC; Mehler PS; Krantz MJ
Addiction; 2015 Sep; 110(9):1468-75. PubMed ID: 26075588
[TBL] [Abstract][Full Text] [Related]
23. Virtual Thorough QT (TQT) Trial-Extrapolation of In Vitro Cardiac Safety Data to In Vivo Situation Using Multi-Scale Physiologically Based Ventricular Cell-wall Model Exemplified with Tolterodine and Fesoterodine.
Patel N; Wisniowska B; Polak S
AAPS J; 2018 Jul; 20(5):83. PubMed ID: 29995258
[TBL] [Abstract][Full Text] [Related]
24. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation.
Gilmour RF; Riccio ML; Locati EH; Maison-Blanche P; Coumel P; Schwartz PJ
J Am Coll Cardiol; 1997 Jul; 30(1):209-17. PubMed ID: 9207644
[TBL] [Abstract][Full Text] [Related]
25. Drug-induced torsades de pointes in an underserved urban population. Methadone: is there therapeutic equipoise?
Romero J; Baldinger SH; Goodman-Meza D; Engstrom K; Valencia CR; Golive A; Medrano F; Rangasamy S; Makkiya M; Fisher JD; Gross J; Krumerman A; Kim S; Garcia MJ; Di Biase L; Ferrick KJ
J Interv Card Electrophysiol; 2016 Jan; 45(1):37-45. PubMed ID: 26589717
[TBL] [Abstract][Full Text] [Related]
26. Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Saint-Gerons DM; Tabarés-Seisdedos R
Eur J Clin Pharmacol; 2021 Oct; 77(10):1513-1521. PubMed ID: 33938974
[TBL] [Abstract][Full Text] [Related]
27. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes.
Gupta A; Lawrence AT; Krishnan K; Kavinsky CJ; Trohman RG
Am Heart J; 2007 Jun; 153(6):891-9. PubMed ID: 17540188
[TBL] [Abstract][Full Text] [Related]
28. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Aström-Lilja C; Odeberg JM; Ekman E; Hägg S
Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):587-92. PubMed ID: 18449951
[TBL] [Abstract][Full Text] [Related]
29. Transient Hypogonadism Is Associated With Heart Rate-Corrected QT Prolongation and Torsades de Pointes Risk During Active Systemic Inflammation in Men.
Lazzerini PE; Cantara S; Bertolozzi I; Accioli R; Salvini V; Cartocci A; D'Errico A; Sestini F; Bisogno S; Cevenini G; Capecchi M; Laghi-Pasini F; Castagna MG; Acampa M; Boutjdir M; Capecchi PL
J Am Heart Assoc; 2022 Jan; 11(1):e023371. PubMed ID: 34935398
[TBL] [Abstract][Full Text] [Related]
30. A case series of drug-induced long QT syndrome and Torsade de Pointes.
Tong KL; Lau YS; Teo WS
Singapore Med J; 2001 Dec; 42(12):566-70. PubMed ID: 11989578
[TBL] [Abstract][Full Text] [Related]
31. Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data.
Kao D; Bucher Bartelson B; Khatri V; Dart R; Mehler PS; Katz D; Krantz MJ
Ann Intern Med; 2013 May; 158(10):735-40. PubMed ID: 23689766
[TBL] [Abstract][Full Text] [Related]
32. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization.
Roden DM
Eur Heart J; 1993 Nov; 14 Suppl H():56-61. PubMed ID: 8293755
[TBL] [Abstract][Full Text] [Related]
33. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
[TBL] [Abstract][Full Text] [Related]
34. QT interval prolongation, torsade de pointes and renal disease.
Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
[TBL] [Abstract][Full Text] [Related]
35. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome.
van Opstal JM; Schoenmakers M; Verduyn SC; de Groot SH; Leunissen JD; van Der Hulst FF; Molenschot MM; Wellens HJ; Vos MA
Circulation; 2001 Nov; 104(22):2722-7. PubMed ID: 11723026
[TBL] [Abstract][Full Text] [Related]
36. QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system.
Pearson EC; Woosley RL
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):747-53. PubMed ID: 15918160
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany.
Sarganas G; Garbe E; Klimpel A; Hering RC; Bronder E; Haverkamp W
Europace; 2014 Jan; 16(1):101-8. PubMed ID: 23833046
[TBL] [Abstract][Full Text] [Related]
38. Doping with aromatase inhibitors and oestrogen receptor modulators in steroid users: Analysis of a forum to identify dosages, durations and adverse drug reactions.
Rochoy M; Danel A; Chazard E; Gautier S; Berkhout C
Therapie; 2022; 77(6):683-691. PubMed ID: 35660259
[TBL] [Abstract][Full Text] [Related]
39. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
40. Acquired drug-induced long QTc: new insights coming from a retrospective study.
De Vecchis R; Ariano C; Di Biase G; Noutsias M
Eur J Clin Pharmacol; 2018 Dec; 74(12):1645-1651. PubMed ID: 30112668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
